Synthetic Bone Graft Substitute

The graft has been cleared by the U.S. Food and Drug Administration (FDA) and has also received the CE Mark.

"OsSatura TCP is the first of four new product launches this year, and the first post-merger launch,” remarked Pieter Wolters, CEO of IsoTis OrthoBiologics. "It is an important expansion of our synthetic product portfolio, reinforcing our position in the synthetic bone graft substitution market, as there is a clear commercial benefit in being able to offer products with different resorption times.”

IsoTis OrthoBiologics was created in 2003 by the merger of GenSci OrthoBiologics, a U.S. company, and IsoTis, a Swiss-Dutch biomedical company.



Related Links:
IsoTis